Ketamine Wellness Centers subsidiary of Delic Holdings Corp (OTCQB:DELCF) (CSE:DELC) (FRA:6X0), has expanded its treatment options to include SPRAVATO nasal spray. The KWC clinics located in Houston, Las Vegas and Seattle will be offering this treatment option beginning April 1.
Taken with an oral antidepressant, SPRAVATO is the FDA-approved esketamine nasal spray for adults with treatment-resistant depression or to treat depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions. Patients interested in this treatment option will first undergo KWC's thorough intake and screening process to ensure they are suitable candidates and would gain the most benefit from the treatment. KWC's clinical protocols ensure SPRAVATO treatments are administered in exactly the right care and patient safety settings.
